Final Overall Survival (OS) Results from a Phase III, Randomized, Open-label, First-line Study of Gefitinib (G) V Carboplatin/Paclitaxel (C/P) in Clinically Selected Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) in Asia (IPASS)
Refereed conference paper presented and published in conference proceedings


Full Text

Other information
All Author(s) ListMOK Shu Kam Tony, YANG H C, FUKUOKA M, WU L Y, THONGPRASERT S, SAIJO N, CHU T D, JIANG H, DUFFIELD L E, ICHINOSE Y
Name of Conference35th ESMO Congress
Country/Region of ConferenceGreat Britain
Proceedings Title35th ESMO Congress
Detailed descriptionorganized by European Society for Medical Oncology,
Year2010
Month10
Place of PublicationUnited Kingdom
Pages2
LanguagesEnglish-United Kingdom
KeywordsGefitinib; NSCLC

Last updated on 2018-23-01 at 20:26